Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avalanche clause in effect

This article was originally published in The Tan Sheet

Executive Summary

FTC on April 24 says HeightMax maker Sunny Health Nutrition Technology & Products must pay its full $1.9 mil. redress for making false and unsubstantiated claims for three dietary supplements. In November, the Riverview, Fla.-based firm said it would pay $375,000 of the settlement agreement due to inability to pay the full amount (1"The Tan Sheet" Dec. 4, 2006, In Brief). However, the avalanche clause included in the settlement states the company must pay the entire $1.9 mil. if the firm misrepresented its finances. FTC said in December it discovered Sunny Health Nutrition possessed an undisclosed PayPal account containing more than $1.8 mil...

You may also be interested in...

FTC settlement

FTC announces Nov. 28 HeightMax Plus maker Sunny Health Nutrition Technology & Products will pay $375,000 to settle charges its advertising claims are deceptive. The settlement also holds the Riverview, Fla.-based company potentially liable for $1.9 mil. in the event it "misrepresented their finances," the release says. Claims include a regular intake of dietary supplement HeightMax results in a 10% to 25% gain in height. The company is also charged with inventing "William Thomson," who was presented in HeightMaxads as an expert with a PhD in Biochemistry. Other products included in the complaint are HeightMax Concentrate, Liposan Ultra Chitosan Fat Blocker and Osteo-Vite. Radio and print advertisements ran in Spanish and English and appeared in Newsweek, Rolling Stone and Maxim...

Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs

The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.

FDA Finalizes Guidance On Blood Glucose Meters With Separate Documents For OTC, Rx Devices

The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts